130 related articles for article (PubMed ID: 8978225)
21. High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison.
Tanaka M; Ino Y; Nakagawa K; Tago M; Todo T
Lancet Oncol; 2005 Dec; 6(12):953-60. PubMed ID: 16321763
[TBL] [Abstract][Full Text] [Related]
22. Therapy for Recurrent High-Grade Gliomas: Results of a Prospective Multicenter Study on Health-Related Quality of Life.
Stöckelmaier L; Renovanz M; König J; Nickel K; Hickmann AK; Mayer-Steinacker R; Nadji-Ohl M; Ganslandt O; Bullinger L; Wirtz CR; Coburger J
World Neurosurg; 2017 Jun; 102():383-399. PubMed ID: 28288921
[TBL] [Abstract][Full Text] [Related]
23. Prognostic awareness and communication preferences among caregivers of patients with malignant glioma.
Applebaum AJ; Buda K; Kryza-Lacombe M; Buthorn JJ; Walker R; Shaffer KM; D'Agostino TA; Diamond EL
Psychooncology; 2018 Mar; 27(3):817-823. PubMed ID: 29125714
[TBL] [Abstract][Full Text] [Related]
24. Daily living with distress and enrichment: the moral experience of families with ventilator-assisted children at home.
Carnevale FA; Alexander E; Davis M; Rennick J; Troini R
Pediatrics; 2006 Jan; 117(1):e48-60. PubMed ID: 16396848
[TBL] [Abstract][Full Text] [Related]
25. Malignant cerebral glioma. Modern radiotherapy can give good quality survival for six months.
Brada M; Thomas D; Rampling R; Crawford P; Burnet N; Byrne P; Sokal M
BMJ; 1997 Mar; 314(7084):899. PubMed ID: 9093111
[No Abstract] [Full Text] [Related]
26. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: Treatment-related late toxicity.
Kortmann RD; Timmermann B; Taylor RE; Scarzello G; Plasswilm L; Paulsen F; Jeremic B; Gnekow AK; Dieckmann K; Kay S; Bamberg M
Strahlenther Onkol; 2003 Sep; 179(9):585-97. PubMed ID: 14628124
[TBL] [Abstract][Full Text] [Related]
27. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
28. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.
Weller M; Müller B; Koch R; Bamberg M; Krauseneck P;
J Clin Oncol; 2003 Sep; 21(17):3276-84. PubMed ID: 12947063
[TBL] [Abstract][Full Text] [Related]
29. End-of-life care in the intensive care unit: a patient-based questionnaire of intensive care unit staff perception and relatives' psychological response.
Hartog CS; Schwarzkopf D; Riedemann NC; Pfeifer R; Guenther A; Egerland K; Sprung CL; Hoyer H; Gensichen J; Reinhart K
Palliat Med; 2015 Apr; 29(4):336-45. PubMed ID: 25634628
[TBL] [Abstract][Full Text] [Related]
30. 12 years' experience with intraoperative radiotherapy (IORT) of malignant gliomas.
Schueller P; Micke O; Palkovic S; Schroeder J; Moustakis C; Bruns F; Schuck A; Wassmann H; Willich N
Strahlenther Onkol; 2005 Aug; 181(8):500-6. PubMed ID: 16044217
[TBL] [Abstract][Full Text] [Related]
31. Application of the MRC brain tumour prognostic index to patients with malignant glioma not managed in randomised control trial.
Latif AZ; Signorini D; Gregor A; Grant R; Ironside JW; Whittle IR
J Neurol Neurosurg Psychiatry; 1998 Jun; 64(6):747-50. PubMed ID: 9647303
[TBL] [Abstract][Full Text] [Related]
32. [Operative therapy of malignant intracranial tumors by the CO2 laser. Initial results after vaporization of the tumors].
Stula D; Gratzl O
Zentralbl Neurochir; 1979; 40(4):343-5, 347-8. PubMed ID: 550652
[TBL] [Abstract][Full Text] [Related]
33. Mood disturbance in glioma patients.
Acquaye AA; Vera-Bolanos E; Armstrong TS; Gilbert MR; Lin L
J Neurooncol; 2013 Jul; 113(3):505-12. PubMed ID: 23677748
[TBL] [Abstract][Full Text] [Related]
34. [Malignant gliomas--radiotherapy].
Schratter-Sehn A
Wien Med Wochenschr; 2006 Jun; 156(11-12):342-5. PubMed ID: 16944365
[TBL] [Abstract][Full Text] [Related]
35. [Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV)].
Pöpperl G; Götz C; Gildehaus FJ; Yousry TA; Reulen HJ; Hahn K; Tatsch K
Nuklearmedizin; 2002 Jun; 41(3):120-8. PubMed ID: 12109031
[TBL] [Abstract][Full Text] [Related]
36. Factors influencing neurocognitive outcomes in young patients with benign and low-grade brain tumors treated with stereotactic conformal radiotherapy.
Jalali R; Mallick I; Dutta D; Goswami S; Gupta T; Munshi A; Deshpande D; Sarin R
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):974-9. PubMed ID: 19864079
[TBL] [Abstract][Full Text] [Related]
37. Radiochemotherapy of malignant glioma in adults. Clinical experiences.
Kortmann RD; Jeremic B; Weller M; Plasswilm L; Bamberg M
Strahlenther Onkol; 2003 Apr; 179(4):219-32. PubMed ID: 12707711
[TBL] [Abstract][Full Text] [Related]
38. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma.
Walker M; Brown J; Brown K; Gregor A; Whittle IR; Grant R
J Neurooncol; 2003 Jun; 63(2):179-86. PubMed ID: 12825822
[TBL] [Abstract][Full Text] [Related]
39. Factors associated with supportive care needs in glioma patients in the neuro-oncological outpatient setting.
Renovanz M; Hechtner M; Janko M; Kohlmann K; Coburger J; Nadji-Ohl M; König J; Ringel F; Singer S; Hickmann AK
J Neurooncol; 2017 Jul; 133(3):653-662. PubMed ID: 28527007
[TBL] [Abstract][Full Text] [Related]
40. A double-edged sword: Should stage IV non-small cell lung cancer patients be informed of their cancer diagnosis?
Yanwei L; Dongying L; Zhuchen Y; Ling L; Yu Z; Zhanyu P
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28266089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
